In-hospital #stroke represents ~3% of all strokes and has a ~2-fold increased mortality rate compared to community-onset stroke. Do you already have an "IN-CODE STROKE"? Great work by @Katha_MD @AlmekhlafiMa @JHolodinsky et al. @DCNSNeuro https://t.co/H0N2dQujAd

Differences of ~1.5 mL, ~7 mL, and ~15 mL in infarct volume corresponded to a 1%, 5%, and 10% higher probability of mRS 0-1 in #stroke pts. Check out our ACT post-hoc analysis. @johanna_ospel @nishita_singh3 @draravindganesh @AlmekhlafiMa @lucianacatanese @American_Heart

#Mondaytip Secondary causes of #hypertension in stroke patients ☝️~1 in 10 have an underlying cause for their elevated BP 🤔Keep high clinical suspicion #CHAPS👉Cushing’s, hyperaldosteronism, aortic coarctation, pheochromocytoma, stenosis of renal arteries https://t.co/FXdbGtuWbS

🧵A more nuanced approach to reperfusion decisions in patients with acute ischemic stroke and large vessel occlusion requires a better understanding of tissue viability, perfusion physiology, & ischemic damage to more accurately predict beneficial, futile, or harmful reperfusion.

https://t.co/MP8qAoETdM

IVT and EVT treatment decision-making in #MeVO #Stroke patients is getting very "cerebral". Take a look at our latest review published in @StrokeAHA_ASA! @johanna_ospel @mhill68 @mayank_G0 @MPeyT1 @NguyenThanhMD @AlmekhlafiMa @bijoymenon

Where does the future🔮 lie for #EVT in acute #stroke due to #MeVO?🤔❓ Here are some ideas for you!👇 https://t.co/m02k8495Ru @UPensato @mayank_G0 @mihill68 @MPeyT1 @DCNSNeuro

The ICH checklist is out, please use it! by Andrea Morotti @DavidSeiffge @PrCCordonnier @stephanamayer & the CODE-ICH team #stroke #intracerebralhemorrhage #timeisbrain https://t.co/0rr1pnUeT0

Reperfusion in #stroke can be beneficial, futile, or harmful. A better understanding of the pathophysiology and overall prognosis can inform our decision-making. @StrokeAHA_ASA @American_Heart @johanna_ospel https://t.co/qNkHNPRbwO

The ICH checklist is out, please use it! by Andrea Morotti @DavidSeiffge @PrCCordonnier @stephanamayer & the CODE-ICH team #stroke #intracerebralhemorrhage #timeisbrain https://t.co/0rr1pnUeT0

In stroke, differences of ~1.5mL, ~7mL, and ~15mL in infarct volume correspond to a 1%, 5%, and 10% higher probability of mRS=0-1. @UPensato @HUNIMED @nishita_singh3 @umanitoba https://t.co/wQuzlpty1L

RT @HemostasisToday: Umberto Pensato (@UPensato) on Reperfusion Outcomes in Stroke @HUNIMED | @UCalgary | @American_Heart https://t.co/iT…

Reperfusion in #stroke can be beneficial, futile, or harmful. A better understanding of the pathophysiology and overall prognosis can inform our decision-making. @StrokeAHA_ASA @American_Heart @johanna_ospel https://t.co/qNkHNPRbwO

A must-read by @UPensato on the probability of excellent outcomes in relation to infarct volume. Essential insights for anyone managing acute stroke care. 👏👏

Amazing #WSC2025 in BCN! My take-home msg: 1. Breakthrough stroke trials are needed 2. Lot of room to be more aggressive in BP lowering for ICH prevention 3. MMA in CSDH is effective 4. Better imaging needed to predict harmful reperfusion 5.TNK over tPA 6. BCN best city in Eur

Differences of ~1.5 mL, ~7 mL, and ~15 mL in infarct volume corresponded to a 1%, 5%, and 10% higher probability of mRS 0-1 in #stroke pts. Check out our ACT post-hoc analysis. @johanna_ospel @nishita_singh3 @draravindganesh @AlmekhlafiMa @lucianacatanese @American_Heart

Day 2 Plenary Session Trials presented #WSC2025 @CSC_Stroke Congratulations, Dr Sylaja PN, for receiving the Presidential Award

Day 1 #WSC2025 @CSC_Stroke

Day 1 #WSC2025 @CSC_Stroke

IPMA of large core EVT trials (ATLAS) showing 60% increase odds of better outcomes. Apparently across any sub analysis (still think there is a group who experience harmful recanalization though) #WSC2025 @WorldStrokeOrg